Three Perspectives. One Economy.
Korea’s KOSDAQ biotech sector is lighting up trading screens in mid-2026, with a wave of small-cap biotech IPOs and share price surges drawing retail and institutional attention alike. But beneath the excitement lies a more complicated story — one of liquidity rotations, questionable valuations, and the age-old question of whether Korean small-caps are genuinely undervalued … Read more
Dawon Systems (다원시스) has secured Phase 1 clinical trial approval for its Boron Neutron Capture Therapy (BNCT) cancer treatment, igniting fierce debate among Korean market watchers. The approval — which came after the company’s preclinical trials demonstrated complete cancer cell remission — has sent ripples through KOSDAQ’s biotech sector and left investors asking one fundamental … Read more
K-Bank’s long-awaited IPO is back on the table, and it arrives at a peculiar moment for Korean financial markets — one defined by a surging KOSPI, a global AI-driven liquidity wave, and growing foreign investor interest in Korean equities. But does the digital banking sector’s headline appeal mask some uncomfortable fundamentals? We gathered our three … Read more